Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection

ABSTRACT Waning mumps IgG antibody and incomplete IgG avidity maturation may increase susceptibility to mumps virus infection in some vaccinees. To measure mumps IgG avidity, serum specimens serially diluted to the endpoint were incubated on a commercial mumps-specific IgG enzyme immunoassay and tre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Mercader, Marcia McGrew, Sun B. Sowers, Nobia J. Williams, William J. Bellini, Carole J. Hickman
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	IgG immunoglobulin avidity immunoassay measles-mumps-rubella vaccine mumps vaccine failure Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/ccfb262526224eea93e98ad0965d66f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ccfb262526224eea93e98ad0965d66f8
record_format	dspace
spelling	oai:doaj.org-article:ccfb262526224eea93e98ad0965d66f82021-11-15T15:22:26ZDevelopment and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection10.1128/mSphere.00320-182379-5042https://doaj.org/article/ccfb262526224eea93e98ad0965d66f82018-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00320-18https://doaj.org/toc/2379-5042ABSTRACT Waning mumps IgG antibody and incomplete IgG avidity maturation may increase susceptibility to mumps virus infection in some vaccinees. To measure mumps IgG avidity, serum specimens serially diluted to the endpoint were incubated on a commercial mumps-specific IgG enzyme immunoassay and treated with the protein denaturant diethylamine (60 mM, pH 10). End titer avidity indices (etAIs [percent ratio of detected diethylamine-resistant IgG at endpoint]) were calculated. Unpaired serum specimens (n = 108) from 15-month-old children living in a low-incidence setting were collected 1 month and 2 years after the first measles, mumps, and rubella vaccine dose (MMR1) and tested for mumps avidity. Per the receiver operating characteristic curve, the avidity assay is accurate (area under the curve, 0.994; 95% confidence interval [CI], 0.956 to 1.000), 96.5% sensitive (95% CI, 87.9 to 99.6%), and 92.2% specific (95% CI, 81.1 to 97.8%) at an etAI of 30%. When 9 sets of paired serum specimens collected 1 to 60 months post-MMR1 were tested for mumps and measles IgG avidity using comparable methods, the mumps etAI increased from 11% to 40 to 60% in 6 months. From 6 to 60 months, avidity was sustained at a mean etAI of 50% (95% CI, 46 to 54%), significantly lower (P < 0.0001) than the mean measles etAI of 80% (95% CI, 74 to 86%). Mean etAIs in children 2 years post-MMR1 (n = 51), unvaccinated adults with distant mumps disease (n = 29), and confirmed mumps cases (n = 23) were 54, 62, and 57%, respectively. A mumps-specific endpoint avidity assay was developed and validated, and mumps avidity was determined to be generally sustained at etAIs of 40 to 60%, reaching etAIs of >80% in some individuals. IMPORTANCE Numerous outbreaks of mumps have occurred in the United States among two-dose measles-mumps-rubella (MMR)-vaccinated populations since 2006. The avidity of mumps-specific IgG antibodies may affect susceptibility to mumps virus infection in some vaccinated individuals. To accurately measure mumps avidity, we developed and validated a mumps-specific IgG avidity assay that determines avidity at the endpoint titer of serially diluted serum specimens, providing results that are independent of IgG concentration. At low antibody titers, endpoint methods are considered more accurate than methods that determine avidity at a single dilution. We determined that 6 months after the first MMR dose, mumps IgG avidity is high and generally sustained at avidity indices of 40 to 60%, reaching values of >80% in some individuals. Additionally, 4% (4/103) of individuals had avidity indices of ≤30% (low avidity) 2 years after vaccination. Inadequate mumps avidity maturation may be one factor influencing susceptibility to mumps virus infection among previously vaccinated or naturally infected individuals.Sara MercaderMarcia McGrewSun B. SowersNobia J. WilliamsWilliam J. BelliniCarole J. HickmanAmerican Society for MicrobiologyarticleIgG immunoglobulinavidity immunoassaymeasles-mumps-rubella vaccinemumpsvaccine failureMicrobiologyQR1-502ENmSphere, Vol 3, Iss 5 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	IgG immunoglobulin avidity immunoassay measles-mumps-rubella vaccine mumps vaccine failure Microbiology QR1-502
spellingShingle	IgG immunoglobulin avidity immunoassay measles-mumps-rubella vaccine mumps vaccine failure Microbiology QR1-502 Sara Mercader Marcia McGrew Sun B. Sowers Nobia J. Williams William J. Bellini Carole J. Hickman Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
description	ABSTRACT Waning mumps IgG antibody and incomplete IgG avidity maturation may increase susceptibility to mumps virus infection in some vaccinees. To measure mumps IgG avidity, serum specimens serially diluted to the endpoint were incubated on a commercial mumps-specific IgG enzyme immunoassay and treated with the protein denaturant diethylamine (60 mM, pH 10). End titer avidity indices (etAIs [percent ratio of detected diethylamine-resistant IgG at endpoint]) were calculated. Unpaired serum specimens (n = 108) from 15-month-old children living in a low-incidence setting were collected 1 month and 2 years after the first measles, mumps, and rubella vaccine dose (MMR1) and tested for mumps avidity. Per the receiver operating characteristic curve, the avidity assay is accurate (area under the curve, 0.994; 95% confidence interval [CI], 0.956 to 1.000), 96.5% sensitive (95% CI, 87.9 to 99.6%), and 92.2% specific (95% CI, 81.1 to 97.8%) at an etAI of 30%. When 9 sets of paired serum specimens collected 1 to 60 months post-MMR1 were tested for mumps and measles IgG avidity using comparable methods, the mumps etAI increased from 11% to 40 to 60% in 6 months. From 6 to 60 months, avidity was sustained at a mean etAI of 50% (95% CI, 46 to 54%), significantly lower (P < 0.0001) than the mean measles etAI of 80% (95% CI, 74 to 86%). Mean etAIs in children 2 years post-MMR1 (n = 51), unvaccinated adults with distant mumps disease (n = 29), and confirmed mumps cases (n = 23) were 54, 62, and 57%, respectively. A mumps-specific endpoint avidity assay was developed and validated, and mumps avidity was determined to be generally sustained at etAIs of 40 to 60%, reaching etAIs of >80% in some individuals. IMPORTANCE Numerous outbreaks of mumps have occurred in the United States among two-dose measles-mumps-rubella (MMR)-vaccinated populations since 2006. The avidity of mumps-specific IgG antibodies may affect susceptibility to mumps virus infection in some vaccinated individuals. To accurately measure mumps avidity, we developed and validated a mumps-specific IgG avidity assay that determines avidity at the endpoint titer of serially diluted serum specimens, providing results that are independent of IgG concentration. At low antibody titers, endpoint methods are considered more accurate than methods that determine avidity at a single dilution. We determined that 6 months after the first MMR dose, mumps IgG avidity is high and generally sustained at avidity indices of 40 to 60%, reaching values of >80% in some individuals. Additionally, 4% (4/103) of individuals had avidity indices of ≤30% (low avidity) 2 years after vaccination. Inadequate mumps avidity maturation may be one factor influencing susceptibility to mumps virus infection among previously vaccinated or naturally infected individuals.
format	article
author	Sara Mercader Marcia McGrew Sun B. Sowers Nobia J. Williams William J. Bellini Carole J. Hickman
author_facet	Sara Mercader Marcia McGrew Sun B. Sowers Nobia J. Williams William J. Bellini Carole J. Hickman
author_sort	Sara Mercader
title	Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
title_short	Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
title_full	Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
title_fullStr	Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
title_full_unstemmed	Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection
title_sort	development and use of an endpoint titration assay to characterize mumps igg avidity following measles, mumps, and rubella vaccination and wild-type mumps infection
publisher	American Society for Microbiology
publishDate	2018
url	https://doaj.org/article/ccfb262526224eea93e98ad0965d66f8
work_keys_str_mv	AT saramercader developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection AT marciamcgrew developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection AT sunbsowers developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection AT nobiajwilliams developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection AT williamjbellini developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection AT carolejhickman developmentanduseofanendpointtitrationassaytocharacterizemumpsiggavidityfollowingmeaslesmumpsandrubellavaccinationandwildtypemumpsinfection
_version_	1718428033282473984

Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection

Ejemplares similares